The influence of men on HPV vaccination of their spouse/partner in China

References

• World Health Organization (WHO). Cervic Uteri; 2021 Jan [accessed 2021 Dec 5]. https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-sheet.pdf
   Google Scholar
• ICO/IARC HPV Information Centre. 2021 Oct 22 [accessed 2021 Dec 5]. https://hpvcentre.net/statistics/reports/CHN_FS.pdf
   Google Scholar
• Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, et al. ICO/IARC information centre on HPV and cancer (HPV Information Centre). Human papillomavirus and related diseases in China. Summary Report 2019 June 17. [accessed 2021 Dec 5].
   Google Scholar
• de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Global Health. 2020;8(2):e180–10. doi:10.1016/S2214-109X(19)30488-7.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Human Papillomavirus (HPV) vaccines; 2021 May 25 [accessed 2021 Dec 5]. https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet
   Google Scholar
• World Health Organization. Draft: global strategy towards the elimination of cervical cancer as a public health problem; 2020 Apr 5 [accessed 2021 Dec 5]. https://www.who.int/publications/m/item/draft-global-strategy-towards-eliminating-cervical-cancer-as-a-public-health-problem
   Google Scholar
• Ferris DG, Brown DR, Giuliano AR, Myers E, Joura EA, Garland SM, Kjaer SK, Perez G, Saah A, Luxembourg A, et al. Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial. Papillomavirus Res. 2020;10:100202. doi:10.1016/j.pvr.2020.100202.
   PubMed Web of Science ®Google Scholar
• Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009;373(9679):1949–57. doi:10.1016/S0140-6736(09)60691-7.
   PubMed Web of Science ®Google Scholar
• Smith JS, Melendy A, Rana RK, Pimenta JM. Age-Specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health. 2008;43(4): S5-e1. doi:10.1016/j.jadohealth.2008.07.009.
   Web of Science ®Google Scholar
• Winer RL, Hughes JP, Feng Q, Xi LF, Lee SK, O’-Reilly SF, … & Koutsky LA, Koutsky LA. Prevalence and risk factors for oncogenic HPV infections in high-risk mid-adult women. Sex Transm Dis. 2012;39(11):848–56. doi:10.1097/OLQ.0b013e3182641f1c.
   PubMed Web of Science ®Google Scholar
• Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda GA, Zhou Y, Jin T. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front Public Health. 2021:1003. doi:10.3389/fpubh.2020.552028.
   Web of Science ®Google Scholar
• Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014;384(9961):2213–27. doi:10.1016/S0140-6736(14)60920-X.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old; 2018 Oct 5 [accessed 2021 Dec 5]. https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-old
   Google Scholar
• Black LL, Zimet GD, Short MB, Sturm L, Rosenthal SL. Literature review of human papillomavirus vaccine acceptability among women over 26 years. Vaccine. 2009;27(11):1668–73. doi:10.1016/j.vaccine.2009.01.035.
   PubMed Web of Science ®Google Scholar
• Weiss TW, Rosenthal SL, Zimet GD. Attitudes toward HPV vaccination among women aged 27 to 45. Int Sch Res Notices. 2011;2011:670318. doi:10.5402/2011/670318.
   Google Scholar
• Lin Y, Lin Z, He F, Chen H, Lin X, Zimet GD, Alias H, He S, Hu Z, Wong LP, et al. HPV vaccination intent and willingness to pay for 2-,4-, and 9-valent HPV vaccines: A study of adult women aged 27–45 years in China. Vaccine. 2020;38(14):3021–30. doi:10.1016/j.vaccine.2020.02.042.
   PubMed Web of Science ®Google Scholar
• Ganle JK, Otupiri E, Parker M, Fitzpatrick R. Socio-Cultural barriers to accessibility and utilization of maternal and newborn healthcare services in Ghana after user-fee abolition. J Matern Child Health. 2015:1–14. doi:10.12966/ijmch.02.01.2015.
   PubMedGoogle Scholar
• Chekole MK, Kahsay ZH, Medhanyie AA, Gebreslassie MA, Bezabh AM. Husbands’ involvement in family planning use and its associated factors in pastoralist communities of Afar, Ethiopia. Reprod Health. 2019;16(1):1–7. doi:10.1186/s12978-019-0697-6.
   PubMed Web of Science ®Google Scholar
• Dudgeon MR, Inhorn MC. Men’s influences on women’s reproductive health: medical anthropological perspectives. Soc Sci Med. 2004;59(7):1379–95. doi:10.1016/j.socscimed.2003.11.035.
   PubMed Web of Science ®Google Scholar
• Namasivayam A, Osuorah DC, Syed R, Antai D. The role of gender inequities in women’s access to reproductive health care: a population-level study of Namibia, Kenya, Nepal, and India. Int J Women’s Health. 2012;4:351. doi:10.2147/IJWH.S32569.
   PubMedGoogle Scholar
• Wong LP. Role of men in promoting the uptake of HPV vaccinations: focus groups’ finding from a developing country. Int J Public Health. 2010;55(1):35–42. doi:10.1007/s00038-009-0072-4.
   PubMed Web of Science ®Google Scholar
• De Groot AS, Tounkara K, Rochas M, Beseme S, Yekta S, Diallo FS, Tracy JK, Teguete I, Koita OA. Knowledge, attitudes, practices and willingness to vaccinate in preparation for the introduction of HPV vaccines in Bamako, Mali. PloS One. 2017;12(2):e0171631. doi:10.1371/journal.pone.0171631.
   PubMed Web of Science ®Google Scholar
• Sathian B, Babu MR, Van Teijlingen ER, Banerjee I, Roy B, Subramanya SH, Rajesh E, Devkota S. Ethnic variations in perception of human papillomavirus and its vaccination among young women in Nepal. Nepal J Epidemiol. 2017;7(1):647. doi:10.3126/nje.v7i1.17757.
   PubMed Web of Science ®Google Scholar
• You D, Han L, Li L, Hu JD, Zimet G, Alias H, Danaee M, Cai L, Zeng F, Wong LP, et al. Human papillomavirus (HPV) vaccine uptake and the willingness to receive the HPV vaccination among female college students in China: a multicenter study. Vaccines. 2020;8(1):31. doi:10.3390/vaccines8010031.
   Web of Science ®Google Scholar
• Song Y, Liu X, Yin Z, Yu W, Cao L, Cao L, Ye J, Li L, Wu J. Human papillomavirus vaccine coverage among the 9-45-year-old female population of China in 2018-2020. Chin J Vaccines Immunization. 2021;27:570–75.
   Google Scholar
• Lin Y, Su Z, Chen F, Zhao Q, Zimet GD, Alias H, & He S, Hu Z, Wong LP. Chinese mothers’ intention to vaccinate daughters against human papillomavirus (HPV), and their vaccine preferences: a study in Fujian Province. Hum Vaccines Immunother. 2021;17(1):304–15. doi:10.1080/21645515.2020.1756152.
   PubMed Web of Science ®Google Scholar
• Champion VL, Skinner CS. The health belief model. Health Behav Health Edu. 2008;4:45–65.
   Google Scholar
• Hosmer DW Jr., Lemeshow S, Sturdivant RX. Applied logistic regression. 3rd ed. Hoboken (NJ): John Wiley & Sons; 2013.
   Google Scholar
• Chen G, Wu B, Dai X, Zhang M, Liu Y, Huang H, … & Wu Z, Wu Z. Gender differences in knowledge and attitude towards HPV and HPV vaccine among college students in Wenzhou, China. Vaccines. 2022;10(1):10. doi:10.3390/vaccines10010010.
   Web of Science ®Google Scholar
• World Health Organization. Human papillomavirus (HPV) and cervical cancer; 2020 Nov 11 [accessed 2021 Dec 5]. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer#:~:text=What%20is%20HPV%3F-,Human%20papillomavirus%20(HPV)%20is%20the%20most%20common%20viral%20infection%20of,shortly%20after%20becoming%20sexually%20active
   Google Scholar
• Ma X, Wang Q, Ong JJ, Fairley CK, Su S, Peng P, Jing J, Wang L, Soe NN, Cheng F, et al. Prevalence of human papillomavirus by geographical regions, sexual orientation and HIV status in China: a systematic review and meta-analysis. Sex Transm Infect. 2018;94(6):434–42. doi:10.1136/sextrans-2017-053412.
   PubMed Web of Science ®Google Scholar
• Li K, Li Q, Song L, Wang D, Yin R. The distribution and prevalence of human papillomavirus in women in mainland China. Cancer. 2019;125(7):1030–37. doi:10.1002/cncr.32003.
   PubMed Web of Science ®Google Scholar
• Li X, Hu SY, He Y, Hernandez Donoso L, Qu KQ, Van Kriekinge G, et al. Systematic literature review of risk factors for cervical cancer in the Chinese population. Women’s Health. 2018;14:1745506518816599. doi:10.1177/1745506518816599.
   Google Scholar
• Hswen Y, Gilkey MB, Rimer BK, Brewer NT. Improving physician recommendations for HPV vaccination: the role of professional organizations. Sex Transm Dis. 2017;44(1):42. doi:10.1097/OLQ.0000000000000543.
   PubMed Web of Science ®Google Scholar
• XinhuaNet. China to introduce premarital counseling at marriage registries; 2020 Sep 10. [accessed 2022 Jan 30]. http://www.xinhuanet.com/english/2020-09/10/c_139356503.htm
   Google Scholar
• Oguntunde O, Nyenwa J, Yusuf FM, Dauda DS, Salihu A, Sinai I. The experience of men who participated in interventions to improve demand for and utilization of maternal and child health services in northern Nigeria: a qualitative comparative study. Reprod Health. 2019;16(1):1–9. doi:10.1186/s12978-019-0761-2.
   PubMedGoogle Scholar